Effect of fat-reformulated dairy food consumption on postprandial flow-mediated dilatation and cardiometabolic risk biomarkers compared with conventional dairy: a randomized controlled trial
posted on 2022-01-14, 11:52authored byOonagh MarkeyOonagh Markey, Dafni Vasilopoulou, Kirsty Kliem, Colette Fagan, Alistair Grandison, Rachel Sutton, David Humphries, Susan Todd, Kim Jackson, David Ian Givens, Julie Lovegrove
Background: Longer-term consumption of saturated fatty acid (SFA)-reduced,
monounsaturated fatty acid (MUFA)-enriched dairy products have been reported to improve
fasting flow-mediated vasodilation (FMD). Yet, their impact on endothelial function in the
postprandial state warrants investigation.
Objective: To compare the impact of a fatty acid (FA)-modified with a conventional (control)
dairy diet on the postprandial %FMD (primary outcome) and systemic cardiometabolic
responses to representative meals, and retrospectively explore whether treatment effects differ
by apolipoprotein (APO)E or endothelial nitric oxide synthase (eNOS) Glu298Asp gene
polymorphisms.
Methods: In a crossover-design randomized controlled study, 52 adults with moderate
cardiovascular disease risk consumed dairy products [38% total energy intake (%TE) from
fat: FA-modified (target: 16%TE SFAs; 14%TE MUFAs) or control (19%TE SFAs; 11%TE
MUFAs)] for 12-wk, separated by an 8-wk washout. Blood sampling and FMD measurements
(0-480 min) were performed pre- and post-intervention after sequential mixed meals that were
representative of the assigned dairy diets (0 min; ~50 g fat; 330 min; ~30 g fat).
Results: Relative to pre-intervention (∆), the FA-modified dairy diet and meals (treatment)
attenuated the increase in the incremental AUC (iAUC), but not AUC, for the %FMD
response observed with the conventional treatment (-135 ± 69 vs +199 ± 82 % x min; P = 0.005). The ∆ iAUC, but not AUC, for the apoB response decreased after FA-modified yet
increased after the conventional treatment (-4 ± 3 vs +3 ± 3 mg/mL x min; P = 0.004). The ∆
iAUC decreased for total plasma SFAs (P = 0.003) and trans 18:1 (P < 0.0001) and increased
for cis-MUFAs (P < 0.0001) following conventional, relative to the FA-modified treatment.
No treatment x APOE- or eNOS-genotype interactions were evident for any outcome.
Conclusions: This study provides novel insights into the longer-term effects of FA-modified
dairy food consumption on postprandial cardiometabolic responses.
This study was registered at clinicaltrials.gov as NCT02089035.
Funding
MICA: Reducing cardiovascular disease risk through replacement of saturated fat in milk and dairy products
This is an Open Access Article. It is published by OUP under the Creative Commons Attribution 4.0 Unported Licence (CC BY). Full details of this licence are available at: http://creativecommons.org/licenses/by/4.0/